Three years ago, the phase 3 ADAURA trial associated osimertinib (Tagrisso, AstraZeneca) with a large disease-free survival (DFS) advantage when it was tested as an adjuvant therapy in resected EGFR-mutated non-small cell lung cancer (NSCLC). But the overall survival (OS) benefit newly established with longer follow-up is a big deal, according to the trial investigators. The trial findings were reported at the 2023 annual meeting of the American Society of Clinical Oncology (abstract
JUNE 12, 2023